SCHEMBL395945

SCHEMBL395945

CCN(CC)C(C(N)=O)n1c(C)c(C(=O)O)c(C)c1C=C1C(=O)Nc2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc21

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 11/20 0.51
▸ NTRK3 Q16288 2/20 0.51
▸ POLB P06746 1/20 0.44
▸ CTDSP1 Q9GZU7 1/20 0.44
▸ NTRK2 Q16620 7/20 0.44
▸ AURKA O14965 1/20 0.44
▸ RAF1 P04049 1/20 0.44
▸ SRC P12931 1/20 0.44
▸ FLT4 P35916 3/20 0.42
▸ KDR P35968 3/20 0.42
▸ FLT3 P36888 3/20 0.42
▸ KIT P10721 1/20 0.42
▸ AURKB Q96GD4 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396230 0.97 NTRK1 (0.56) NTRK1NTRK3POLBCTDSP1NTRK2
SCHEMBL397868 0.94 NTRK1 (0.52) NTRK1NTRK3POLBCTDSP1NTRK2
SCHEMBL393780 0.93 NTRK1 (0.52) NTRK1NTRK3POLBCTDSP1NTRK2
SCHEMBL399058 0.91 FLT3 (0.48) NTRK1AURKAFLT4KDRFLT3
SCHEMBL397947 0.90 NTRK1 (0.58) NTRK1NTRK3POLBCTDSP1NTRK2
SCHEMBL394525 0.89 FLT3 (0.51) NTRK1NTRK3AURKAFLT4KDR
SCHEMBL396850 0.89 NTRK1 (0.53) NTRK1NTRK3NTRK2AURKARAF1
SCHEMBL394406 0.87 NTRK2 (0.59) NTRK1POLBNTRK2AURKARAF1
SCHEMBL395675 0.86 NTRK1 (0.61) NTRK1NTRK3POLBNTRK2AURKA
SCHEMBL396895 0.86 NTRK1 (0.66) NTRK1NTRK3POLBNTRK2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback